Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of DirectorsGlobeNewsWire • 08/13/20
New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic ConditionsGlobeNewsWire • 08/10/20
Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020GlobeNewsWire • 08/06/20
Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS TestGlobeNewsWire • 07/29/20
Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®GlobeNewsWire • 07/28/20
Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.GlobeNewsWire • 07/22/20
Myriad Announces New Studies Validating the Ability of Myriad’s riskScore® Test to Modify Breast Cancer Risk PredictionGlobeNewsWire • 07/07/20
Myriad Announces Partnership with OptraHEALTH® to Deliver “Gene™” a New AI Based Information Tool for Hereditary Cancer PatientsGlobeNewsWire • 07/06/20
New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological AssessmentGlobeNewsWire • 06/25/20
Myriad Announces New Favorable Coverage Policies for Prolaris® from Three New Commercial Health Plans Including Major National ProviderGlobeNewsWire • 06/15/20
Palmetto GBA Issues Final Local Coverage Determination on Pharmacogenomic Testing for Medicare BeneficiariesGlobeNewsWire • 06/11/20